Welcome to our dedicated page for Jazz Pharmaceuticals Plc news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals Plc stock.
Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) is a global biopharmaceutical leader developing life-changing therapies for complex conditions in oncology, neuroscience, and sleep medicine. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate milestones, regulatory developments, and clinical research advancements.
Our curated collection features official press releases, earnings reports, and analysis of strategic initiatives. Users can track key updates including FDA regulatory decisions, clinical trial results, and therapeutic portfolio expansions. The resource prioritizes accuracy and comprehensiveness, serving as a primary source for understanding Jazz's market position.
Content spans multiple categories essential for informed decision-making: product approvals, research collaborations, financial performance, and manufacturing updates. Each entry maintains strict editorial standards to ensure relevance to both clinical and investment communities.
Bookmark this page for streamlined access to Jazz Pharmaceuticals' latest developments. Check regularly for updates on innovative therapies addressing narcolepsy, epilepsy, and hematologic malignancies, supported by the company's established R&D expertise.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. Mr. Riga joined Jazz in April 2025 through the acquisition of Chimerix and previously served as chief operating and commercial officer at Chimerix, where he directed corporate strategy and led the transaction that sold Chimerix to Jazz. He helped navigate the regulatory process for U.S. approval and launch of Modeyso (dordaviprone), the first approved therapy for H3K27M-mutant diffuse midline glioma. Management says Riga has 25+ years of industry experience and led over $2 billion in business development deals in the past five years.
Jazz Pharmaceuticals (Nasdaq: JAZZ) reported positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2+ locally advanced or metastatic GEA. Both Ziihera arms (with chemotherapy, and with tislelizumab plus chemotherapy) showed ~35% reduction in progression or death versus trastuzumab plus chemotherapy, with median PFS >1 year (~12.4 months vs 8.1 months).
The Ziihera+tislelizumab arm reached a median overall survival of 26.4 months (OS HR 0.72; P=0.0043), a >7-month improvement versus control; Ziihera+chemo showed median OS 24.4 months (OS HR 0.80; P=0.0564) with a strong positive trend. Safety was consistent with HER2 and immunotherapy profiles; higher Grade ≥3 TRAEs and diarrhea rates were reported with the combination including tislelizumab.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will host investor webcasts in January 2026 to review clinical and corporate updates.
Key events: a zanidatamab HERIZON-GEA-01 Phase 3 results webcast on Jan 9, 2026 at 6:30 a.m. PT / 3:30 p.m. GMT following the oral presentation at ASCO GI on Jan 8, 2026; and a corporate presentation by CEO Renee Gala at the J.P. Morgan Healthcare Conference on Jan 13, 2026 at 11:15 a.m. PST / 7:15 p.m. GMT.
Audio webcasts and 30-day replays will be available via the Investors section of Jazz Pharmaceuticals' website.
Jazz Pharmaceuticals (Nasdaq: JAZZ) presented 20 abstracts at World Sleep 2025 and Psych Congress 2025 including Phase 4 DUET data for Xywav (low-sodium oxybate).
Key findings: DUET showed fewer awakenings and reduced wake after sleep onset, reduced sleep inertia and improved objective alertness in idiopathic hypersomnia, and additional symptom benefit in a >9 g nightly cohort (n=48). Real-world analyses flagged elevated sodium-associated cardiovascular, cardiometabolic and renal risks in people with narcolepsy or IH. Safety at <9 g/night was consistent with Xywav’s known profile.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will present eight abstracts, including four late-breaking posters, on Epidiolex (cannabidiol) at the American Epilepsy Society 2025 meeting (Dec 5–9, 2025) in Atlanta.
Key findings include a 6-month intermediate EpiCom analysis showing reductions in TAND-SQ and ABC subscale scores and caregiver/clinician‑reported behavioral severity after 26 weeks of adjunctive Epidiolex in tuberous sclerosis complex; a Phase 1 PK study finding no pharmacokinetic interaction between Epidiolex and cenobamate; preclinical synergistic PD effects with cenobamate; and multiple real-world analyses reporting reduced polypharmacy, antiseizure‑medication cycling, healthcare resource utilization, and seizure frequency versus external control.
Jazz Pharmaceuticals (NASDAQ: JAZZ) announced that Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) combinations in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma will be presented as a late-breaking oral abstract at ASCO GI, Jan 8–10, 2026. The release notes highly statistically significant, clinically meaningful improvements in progression-free survival (PFS) for both Ziihera regimens versus trastuzumab plus chemotherapy, and statistically significant overall survival (OS) improvement for Ziihera plus tislelizumab and chemotherapy; Ziihera plus chemotherapy showed a clinically meaningful OS effect with a strong trend toward significance. A post-hoc OS analysis from HERIZON-BTC-01 in previously treated HER2+ biliary tract cancer will also be presented. Jazz will host an investor webcast on Jan 9, 2026 to review the data.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will participate in Citi's 2025 Global Healthcare Conference. Management will appear in a fireside chat on December 2, 2025 at 6:45 a.m. PST / 9:45 a.m. EST / 2:45 p.m. GMT. An audio webcast of the fireside chat will be available via the Investors section of Jazz Pharmaceuticals' website and a replay will be archived for 30 days.
Jazz Pharmaceuticals is a global biopharma focused on therapies for sleep disorders, epilepsy, and oncology, with R&D, manufacturing, and employees in multiple countries. For investor access, visit the company's investor events and presentations page.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced positive top-line Phase 3 HERIZON-GEA-01 results on Nov 17, 2025 for Ziihera (zanidatamab-hrii) in first-line HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma.
Both Ziihera+chemotherapy and Ziihera+tislelizumab+chemotherapy showed statistically significant PFS improvements versus trastuzumab+chemotherapy; the triplet also showed statistically significant OS benefit, while the doublet showed a clinically meaningful OS effect with a strong trend toward significance at first interim analysis. Jazz plans a U.S. sBLA submission in 1H 2026 and will seek guideline adoption and medical meeting presentation in early 2026.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will present five abstracts at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting, November 19–23 in Honolulu.
Presentations highlight clinical and preclinical data for Modeyso (dordaviprone) in H3 K27M-mutant diffuse midline glioma, translational work on molecular pathways and combination strategies, immune‑modulatory effects, and new preclinical results for JZP3507 (ONC206) in CNS tumors.
Key sessions include oral and poster presentations on Nov 21–23 with multiple pediatric and rare tumor abstracts.
Jazz Pharmaceuticals (Nasdaq: JAZZ) reported 3Q25 total revenues of $1.126B, up 7% year‑over‑year, driven by Xywav, Epidiolex and the Modeyso launch. Modeyso received FDA accelerated approval and generated $11.0M in 3Q25 after an August launch. Xywav sales were $431.4M (+11%) and Epidiolex was $302.6M (+20%). GAAP net income for 3Q25 was $251.4M and non‑GAAP adjusted net income was $500.7M. Cash and investments were $2.0B with long‑term debt of $5.4B. Company narrowed 2025 revenue guidance to $4,175–$4,275M and provided updated GAAP and non‑GAAP guidance.
FAQ
What is the current stock price of Jazz Pharmaceuticals Plc (JAZZ)?
What is the market cap of Jazz Pharmaceuticals Plc (JAZZ)?
